Model: Young acquired niacin dependency (ANDY) mice. 
Dosage: 30 mg/kg/day of niacin

Mice engineered to have low body-wide NAD+ levels exhibit a shortened lifespan and widespread physical decline, which is largely reversed with the NAD+ booster niacin. 

Model: 6-week-old ICR mice
Dosage: 250 mg/kg per day or 500 mg/kg per day of glucosamine and 100 mg/kg per day or 200 mg/kg per day of aspirin for either eight (acute alcohol exposure model) or 40 days (chronic alcohol exposure model)

New Study Supports Repurposing Glucosamine Against Liver Aging

A sugar-like compound found in cartilage called glucosamine reduces dysfunctional cells (senescent cells) in the liver and attenuates liver damage from alcohol consumption in mice.

(Glucosamine capsules | MedicalNewsToday)

Glucosamine alleviates liver damage from alcohol consumption in mice, supporting its potential for use against alcoholic liver disease.

Aging &amp; Longevity

Finalist Teams Awarded $1 Million in XPrize Healthspan Contest to Transform Healthy Aging

The XPrize Healthspan—which will split $101 million among teams developing therapeutics to restore muscle, cognitive, and immune function in older adults—has named 10 teams receiving $1 million each.

(XPrize announced the finalists for its XPrize Healthspan competition | XPrize)

The XPrize Healthspan competition has named its top 20 finalist groups that will submit their aging intervention therapies for human trial testing.

Model: Male Wistar rats 
Dosage: 1.5 g/kg/day of orally administered glycine for 5 months

Glycine, an amino acid shown to extend the lifespan of mice, moderately extends the lifespan of flies and counters brain and muscle degeneration in aged rats. 

Model: Six adults who received intravenous NAD+ and eight adults who received intravenous NR
Dosage: 500 mg of intravenous NAD+ or 500 mg of intravenous NR daily for four consecutive days

Pilot Human Study Supports Safety of NAD+ IV and NR IV Infusions

A Stanford study supports the short-term safety of NAD+ and NR infusion therapies, and participants who received NR infusions exhibited significantly lower HbA1c (a blood test that reflects average blood sugar over two to three months).

(An IV bag containing a solution with NAD+ | Crete Fertility Centre)

A Stanford human trial provides the first data supporting the safety of NAD+ IV and NR IV therapies.

Search Result: Cholesterol

New Mayo Clinic Study: Forcibly Depleting NAD+ Shortens Lifespan

New Study Supports Repurposing Glucosamine Against Liver Aging and Alcoholic Liver Disease

10 Finalist Teams Awarded $1 Million in XPrize Healthspan Contest to Transform Healthy Aging

Glycine Extends Life & Counters Brain and Muscle Degeneration, New Study Shows

Pilot Human Study Supports Safety of NAD+ IV and NR IV Infusions